JHVEPhoto Overview Pfizer (NYSE:PFE) (NEOE:PFE:CA) has struggled to gain any sort of recovery momentum since it suffered losses in revenue coming off the tail end of the pandemic. In addition, the upcoming patent expiries seem to be a source of concern for many investors here as we try to figure out how PFE will whether…
Alexandros Michailidis Investment thesis My previous bullish thesis about Pfizer Inc. (NYSE:PFE) from October 2023 did not age well, as the stock delivered a -10% total return over the last half-year, substantially lagging behind the broader market. Despite it, today I want to reiterate my bullish thesis because recent developments suggest that the business continues…
Angelo D’Amico/iStock via Getty Images Pfizer (NYSE:PFE) has had a rough few quarters. Following a massive boom in revenue and profits that was the direct result of the company’s prominent Covid products – including the vaccine (Comirnaty) and Paxlovid – shares have plunged as the pandemic has broadly receded as a global threat: TradingView However,…
Pfizer Inc. (NYSE:PFE) TD Cowen 44th Annual Health Care Conference March 4, 2024 11:10 AM ET Company Participants David Denton – Chief Financial Officer and Executive Vice President Conference Call Participants Steve Scala – TD Cowen Steve Scala Well, good morning once again. We’re delighted to have Pfizer here at Cowen’s 44th Annual Healthcare Conference….
olm26250 Introduction Over the past few weeks, I have often told people I’m getting a 2021 feeling, as the market is rapidly rising, boosted by a few select tech/growth stocks. Meanwhile, crypto assets are flying again, boosted by Federal Reserve rate expectations that may not be fully justified in light of sticky inflation. The other…
georgeclerk Pfizer Inc. (NYSE:PFE) has been in a major downtrend since late 2021 as the pandemic boom of Covid vaccinations started to decline. The bears have some valid concerns, but it appears that the negative sentiment has overshot reality. I have a fairly neutral view of the company, but I like the stock itself when…
Michael M. Santiago Pfizer (NYSE:PFE) submitted a better than expected earnings card for the fourth fiscal quarter last week. Despite a drop-off in COVID-19 related product revenues, Pfizer has been able to deliver solid organic top line growth in the fourth quarter as well as FY 2023. The pharmaceutical giant also confirmed its financial outlook…
JHVEPhoto Pfizer Inc. (NYSE:PFE) stock has continued to reel from the exhaustion of COVID dollars. Specifically, the 2023 downturn has been primarily dragged by a faster-than-expected normalization of Comirnaty vaccine and Paxlovid COVID treatment uptakes. In addition to the $5.6 billion write-off on Paxlovid/Comirnaty inventory in Q3, management has also provided a weaker-than-expected guidance for…
PixelsEffect A logical pick cut in half There haven’t been many, if any drawdowns of this caliber to grab Pfizer (NYSE:PFE) -50% off highs. The company is down for good reason, investment in the Covid Vaccine solutions has left the company behind from an R&D perspective. While products related to MRNA Covid vaccines continue to…
nathaphat Thesis I was initially interested in buying Pfizer (NYSE:PFE) but after deeper research, I got more and more reluctant to pull the trigger. So I am rating it a ‘Neutral/Hold’ for now. Here’s my narrative for Pfizer: Pfizer needs new revenue streams in a post-COVID world with patent cliffs on the horizon Patent cliffs…
DNY59 Pfizer Inc. (NYSE:PFE) has been one of the most frustrating companies in my coverage, as my previous bullish thesis on the leading biopharma leader hasn’t panned out. The company’s outlook on its COVID franchise has proved to be more challenging than anticipated, leading to over-optimistic Wall Street estimates. As a result, I believe the…
DamianKuzdak We previously covered Pfizer (NYSE:NYSE:PFE) in September 2023, discussing its pessimistic performance as the decelerating COVID-19 portfolio and underperforming bolt-on acquisitions had contributed to its lowered FY2023 guidance range. Combined with the overly aggressive R&D efforts, expensive acquisitions, and deteriorating balance sheet, we had preferred to cautiously rate the stock as a Hold then….
Dan Kitwood Introduction Over the last few months, the indexes have been carried by the big tech stocks. While the rest of the market has struggled and many stocks have been struggling. As such, some interesting value opportunities are now arising. You might be thinking, “The economy is struggling, the market outlook isn’t great, and…
Joe Raedle After hours on Friday, Pfizer (NYSE:PFE) dropped a bomb on the market. The biopharma benefitted greatly from COVID vaccine and treatment-related drug sales and the company is getting hit hard by the flip side of those sales disappearing. My investment thesis remains Neutral on the stock as Pfizer has likely hit bottom, but…
Pfizer Inc. (NYSE:PFE) Cantor Fitzgerald Annual Global Health Conference Call September 26, 2023 3:30 PM ET Company Participants Albert Bourla – Chairman & CEO Conference Call Participants Louise Chen – Cantor Fitzgerald Louise Chen All right. Good day, everybody. Thank you for joining us for our keynote address with the Chairman and CEO of Pfizer,…
Pfizer Inc. (NYSE:PFE) Citi’s 18th Annual BioPharma Conference September 7, 2023 10:30 AM ET Company Participants Mikael Dolsten – Chief Scientific Officer & President, Pfizer Research & Development Christopher Stevo – SVP & Chief IR Officer Conference Call Participants Andrew Baum – Citi Andrew Baum So delighted to introduce Mikael Dolsten. Mikael is President R&D,…
Pfizer Inc. (NYSE:PFE) Wells Fargo Securities Healthcare Conference September 6, 2023 12:45 PM ET Company Participants Chris Stevo – SVP and Chief IR Officer Annaliesa Anderson – SVP and Head of Vaccine R&D Rodrigo Puga – Lead, U.S. Commercial and Global Business Conference Call Participants Mohit Bansal – Wells Fargo Mohit Bansal Great. Thank you…
tiero The PFE Investment Thesis Remains Shaky Here We previously covered Pfizer (NYSE:PFE) in May 2023, discussing its mediocre historical stock performance compared to its pharmaceutical peers. Most of the pessimism was attributed to the decelerating COVID-19 portfolio and $22B worth of annualized patent cliff from 2025 onwards. This was on top of the overly…